Arya Pharma is implementing the Class II Type A recall in consultation with Sahpra and in accordance with the Medicines and Related Substances Act 101 of 1965, as amended.
The FDA has classified the action as a Class II recall, indicating that the affected product may cause temporary or medically reversible adverse health effects, although the likelihood of serious health consequences remains low.